# OnCo record infigratinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/infigratinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "infigratinib" ;
  schema:name "Infigratinib"@en ;
  schema:alternateName "BGJ398"@en, "Truseltiq" ;
  schema:description "Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead."@en ;
  schema:url <https://onco.cc/drugs/infigratinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Infigratinib> ;
  schema:citation <https://en.wikipedia.org/wiki/Infigratinib>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1852688> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Oral FGFR1 to 3 kinase inhibitor" ;
  onco:approval "US 2021: Previously treated unresectable or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement (accelerated approval)" ;
  onco:acceleratedApproval "US 2021-05-28: Treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangement as detected by an FDA approved test" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:drugs <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/futibatinib/> ;
  onco:companies <https://onco.cc/companies/bridgebio-oncology-therapeutics/>, <https://onco.cc/companies/helsinn/> ;
  onco:trials <https://onco.cc/trials/nct02159066/>, <https://onco.cc/trials/nct01975701/>, <https://onco.cc/trials/nct02706691/> .